Intercept Pharmaceuticals Inc
NASDAQ:ICPT 3:59:54 PM EDT
| Market Cap (Intraday) | 567.52M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $16.73 |
| 50-Day MA | $16.86 |
| 200-Day MA | $17.41 |
Intercept Pharmaceuticals Inc Stock, NASDAQ:ICPT
10 Hudson Yards, 37th floor, New York, New York 10001
United States of America
Phone: +1.646.747.1000
Number of Employees: 498
Description
Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the research, development and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.